Condor Capital Management Has $10.78 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 9th, 2023

Condor Capital Management lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 61,009 shares of the company’s stock after selling 1,858 shares during the period. Johnson & Johnson accounts for 1.3% of Condor Capital Management’s holdings, making the stock its 18th biggest holding. Condor Capital Management’s holdings in Johnson & Johnson were worth $10,777,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of JNJ. Nordwand Advisors LLC bought a new position in Johnson & Johnson during the fourth quarter worth $785,273,000. Savant Capital LLC raised its stake in Johnson & Johnson by 8,568.8% during the fourth quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after buying an additional 3,588,251 shares during the last quarter. Edmp Inc. raised its stake in Johnson & Johnson by 17,222.9% during the fourth quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after buying an additional 3,204,658 shares during the last quarter. Vanguard Group Inc. raised its stake in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after buying an additional 2,815,655 shares during the last quarter. Finally, GQG Partners LLC raised its stake in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Down 0.2 %

Johnson & Johnson stock opened at $162.31 on Tuesday. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35. The stock has a market cap of $421.80 billion, a PE ratio of 33.96, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. The firm’s 50-day simple moving average is $158.46 and its 200 day simple moving average is $166.96. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.77 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. During the same period in the previous year, the company earned $2.67 earnings per share. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.93%. Johnson & Johnson’s payout ratio is 99.58%.

Analyst Ratings Changes

Several research firms have weighed in on JNJ. Piper Sandler decreased their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. UBS Group began coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Atlantic Securities decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Finally, Guggenheim began coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $173.00.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.